肠易激综合症 · IBS

参考文献 · 13

1. Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016). Bowel disorders (Rome IV criteria). Gastroenterology, 150(6), 1393-1407. 10.1053/j.gastro.2016.02.031
2. Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021). ACG clinical guideline: management of irritable bowel syndrome. The American Journal of Gastroenterology, 116(1), 17-44. Graded recommendations include a positive diagnostic strategy over one of exclusion (strong, high quality), a limited trial of a low-FODMAP diet (conditional, very low quality), rifaximin for global IBS-D symptoms (strong, moderate quality), mixed opioid agonists/antagonists such as eluxadoline (conditional, moderate quality), and alosetron for women with severe IBS-D who have failed conventional therapy (conditional, low quality). 10.14309/ajg.0000000000001036
3. Sperber, A. D., Bangdiwala, S. I., Drossman, D. A., Ghoshal, U. C., Simren, M., Tack, J., et al. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology, 160(1), 99-114.e3. Across 33 countries, IBS prevalence was 4.1% under Rome IV criteria versus 10.1% under the looser Rome III criteria in the Internet survey (1.5% vs 3.5% in the household survey) — the criteria version, not the population, accounts for most of the spread between commonly quoted prevalence figures. 10.1053/j.gastro.2020.04.014
4. Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014). A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology, 146(1), 67-75. Randomized controlled cross-over trial; a low-FODMAP diet significantly reduced overall IBS symptoms versus a typical Australian diet. Onion and garlic are among the highest-fructan (FODMAP) foods. 10.1053/j.gastro.2013.09.046
5. Tuck, C. J., Reed, D. E., Muir, J. G., & Vanner, S. J. (2020). Implementation of the low FODMAP diet in functional gastrointestinal symptoms: a real-world experience. Neurogastroenterology & Motility, 32(1), e13730. 10.1111/nmo.13730
6. Gibson, P. R. (2017). The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy? Journal of Gastroenterology and Hepatology, 32(S1), 32-35. Six RCTs comparing the low FODMAP diet with placebo approaches were uniformly positive; real-world experience confirms that about 70% of patients respond, and the author concludes a dietitian-led low FODMAP diet should be considered a first-line therapy in IBS. 10.1111/jgh.13693
7. van Nood, E., Vrieze, A., Nieuwdorp, M., et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. The New England Journal of Medicine, 368(5), 407-415. 10.1056/NEJMoa1205037
8. Suez, J., Zmora, N., Zilberman-Schapira, G., et al. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell, 174(6), 1406-1423.e16. 10.1016/j.cell.2018.08.047
9. Besselink, M. G., van Santvoort, H. C., Buskens, E., et al. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial (PROPATRIA). The Lancet, 371(9613), 651-659. 10.1016/S0140-6736(08)60207-X
10. Bonaz, B., Bazin, T., & Pellissier, S. (2018). The vagus nerve at the interface of the microbiota-gut-brain axis. Frontiers in Neuroscience, 12, 49. The vagus is a mixed nerve about 80% afferent (gut/viscera to brain), a principal bidirectional pathway of the gut-brain axis. 10.3389/fnins.2018.00049
11. Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. New England Journal of Medicine, 364(1), 22-32. Two identically designed phase 3 trials (TARGET 1 and TARGET 2): rifaximin 550 mg three times daily for 2 weeks produced adequate relief of global IBS symptoms in 40.7% of patients versus 31.7% on placebo (P < .001) over the 10-week follow-up. 10.1056/NEJMoa1004409
12. U.S. Food and Drug Administration. (2024, July). VIBERZI (eluxadoline) tablets, for oral use, CIV — full prescribing information. Contraindicated in patients without a gallbladder because of an increased risk of pancreatitis and sphincter of Oddi spasm; most serious cases began within a week of starting treatment and some after only one or two doses, and fatal cases have been reported in patients without a gallbladder. Also contraindicated with biliary duct obstruction or sphincter of Oddi disease, alcohol misuse or more than 3 alcoholic drinks daily, prior pancreatitis, severe hepatic impairment, and chronic or severe constipation. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7821bd40-4c84-4984-951b-6436ae20421a
13. U.S. Food and Drug Administration. (2019, April). LOTRONEX (alosetron hydrochloride) tablets, for oral use — full prescribing information. Boxed warning: infrequent but serious gastrointestinal adverse reactions, including ischaemic colitis and serious complications of constipation, have led to hospitalisation and rarely to blood transfusion, surgery, and death. Indicated only for women with severe diarrhoea-predominant IBS of generally six months or longer who have not responded to conventional therapy, and it must be stopped immediately if constipation or symptoms of ischaemic colitis appear. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c216e967-436f-475a-8e6a-2ad11adc63af